Evidence map›Paper›PMID 42735303›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Local delivery of interferon restores antigen presentation and sensitizes medulloblastoma to T cell killing.

Tanja Eisemann, Kendall R Chambers, Meher Beigi Masihi, Theophilos Tzaridis, Sajina Gc, Veronika Pister, Isaac Youm, Aditi Dutta, Alexander T Wenzel, Koei Chin and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Tanja EisemannCancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.ORCID 0000-0001-5981-6491
Kendall R ChambersCancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.ORCID 0000-0001-6367-780X
Meher Beigi MasihiCancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
Theophilos TzaridisCancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
Sajina GcDepartment of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY 10032.ORCID 0000-0003-2676-2794
Veronika PisterDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.ORCID 0000-0002-8051-4890
Isaac YoumDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, OR 97239.
Aditi DuttaCancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
Alexander T WenzelDepartment of Medicine, University of California San Diego, La Jolla, CA 92093.ORCID 0000-0002-2056-2938
Koei ChinDepartment of Biomedical Engineering, Oregon Health and Science University, Portland, OR 97239.
Zhenhua XuBrain Tumor Institute, Center for Cancer and Immunology, Children's National Hospital, Washington, DC 20010.ORCID 0000-0001-9481-5611
Yanxin PeiBrain Tumor Institute, Center for Cancer and Immunology, Children's National Hospital, Washington, DC 20010.
Scott L PomeroyDepartment of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA 20037.ORCID 0000-0003-2102-686X
Jill P MesirovCancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
Ernest FraenkelDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.ORCID 0000-0001-9249-8181
Anindya BagchiCancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.
Lukas ChavezCancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.ORCID 0000-0002-8718-8848
Robert J Wechsler-ReyaCancer Genome and Epigenetics Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037.ORCID 0000-0002-7463-8352

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
Understanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5M
Predoctoral and Postdoctoral Training in Cancer Cell BiologyT32CA067754 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEAN Y.J. WANG · 1995 to 2026
$6.5M
Identifying and Targeting the Drivers of Pediatric Brain TumorsR35NS122339 · NINDS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Robert J. Wechsler-Reya · 2021 to 2026
$3.6M
Identifying therapeutic pathways targeting medulloblastoma-immune cell interactionsU01CA253547 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FRAENKEL, ERNEST, MESIROV, JILL P. · 2021 to 2025
$2.7M
High Performance Computing and Machine Learning Infrastructure for Oregon Life SciencesS10OD034224 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLROTT, KYLE · 2023 to 2023
$2.0M
Methods for improved detection of activated molecular pathways in cancerF31CA257344 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WENZEL, ALEXANDER THOMAS · 2021 to 2023
$122k
HHS | NIH | National Cancer Institute (NCI) F31CA257344HHS | NIH | National Cancer Institute (NCI) P30 CA030199HHS | NIH | National Cancer Institute (NCI) T32CA067754HHS | NIH | National Cancer Institute (NCI) U01 CA253547HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R35 NS122339NCI NIH HHS F31 CA257344NCI NIH HHS P30 CA013696NCI NIH HHS P30 CA030199NCI NIH HHS P30 CA069533NCI NIH HHS T32 CA067754NCI NIH HHS U01 CA253547NIH HHS S10 OD034224NINDS NIH HHS R35 NS122339
6 · The paper itself

Abstract

Medulloblastomas are considered immunologically cold and refractory to immunotherapy. One factor contributing to their low immunogenicity is impaired antigen presentation, which allows tumor cells to evade cytotoxic T cells. Using a syngeneic mouse model of medulloblastoma, we demonstrate that despite low expression of MHC class I on tumor cells, depletion of CD8

Indexed as

Antigen PresentationCD8-Positive T-LymphocytesCerebellar NeoplasmsInterferon-gammaMedulloblastomaAnimalsCell Line, TumorHistocompatibility Antigens Class IMiceMice, Inbred C57BLT-Lymphocytes, CytotoxicHistocompatibility Antigens Class IInterferon-gammaantigen presentationCD8+ T cellsconvection-enhanced deliveryinterferon gammamedulloblastoma

Identifiers

PMID42735303
PMCPMC13598174

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.